- Evoke Pharma (NASDAQ:EVOK) announces positive findings from a second market research study conducted for GIMOTI (metoclopramide) nasal spray.
- The study aimed to gather further market insights on perception of GIMOTI in the GI community.
- In May 2021, Evoke’s commercialization partner, EVERSANA, conducted the GIMOTI Awareness, Trial, Usage (ATU) Study.
- The study objectives were to understand the current gastroparesis treatment landscape and to evaluate physicians’ perceptions of GIMOTI following recent brand marketing efforts. Key findings are as follows:
- Continued increase in intent to prescribe GIMOTI with 81% of all respondents intend to prescribe GIMOTI in the future.
- Targeted gastroenterologists (GIs) report greater GIMOTI usage across first, second and third lines of treatment from the December 2020 study, with the most significant increase as a third-line treatment option from 16% to 24%.
- The percentage of targeted GIs reporting high awareness of GIMOTI (scoring a 4 or 5 out of 5) has increased from 21% in December 2020 to 46% in May 2021.
- Targeted GIs report increased in-person visits by sales representatives. Importantly 75% of target GIs stated they would prefer future interactions to be in-person vs 64% in the previous study.
- The Company will discuss the findings at upcoming GI ReConnect Conference, being held on June 18-19th in Napa Valley, CA.
- EVOK shares up 2.8% premarket.
- Earlier, Jan.13: Evoke Pharma shares surge on positive findings from Gimoti market research study